Merck & Co., Inc.'s third-quarter 2010 earnings call presented several positive and stable elements that are likely to have a favorable short-term impact on the stock price. Here are the key points:

- **Strong Financial Performance**: Merck reported non-GAAP EPS of $0.85, exceeding expectations, and achieved solid revenue growth driven by key products like JANUVIA, JANUMET, SINGULAIR, ISENTRESS, and REMICADE[3].
- **Merger Synergies**: The company is on track to achieve its synergy target of $3.5 billion in annual savings by the end of 2012, which is a significant cost-saving achievement[3].
- **Robust Pipeline**: Merck has a strong late-stage pipeline with promising candidates, including boceprevir, odanacatib, and anacetrapib, which are expected to contribute to future growth[3].
- **Global Expansion**: The company is making significant progress in emerging markets, with a focus on expanding its product portfolio and improving access to healthcare in these regions[3].
- **Cost Management**: Effective control over expenses, including reduced marketing and administrative costs, further supports the company's financial health[3].

Given these positive factors, including strong financial performance, successful integration of the merger, and a robust pipeline, the stock is likely to see a positive short-term impact.

[1]